EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study

Diogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, Bernardo Pereira, Leonor Vasconcelos de Matos, Leonor Fernandes, Guilherme Nader-Marta, Michel Moreau, Donatienne Taylor, Francois P Duhoux, Evandro de Azambuja · 2026 · Breast Cancer Research and Treatment · Atlas ID MAR2026

What this study shows

Everolimus added to endocrine therapy provided modest but statistically significant PFS benefit (5.0 vs 4.3 months; HR 0.68) in ER+/HER2- advanced breast cancer post-CDK4/6 inhibitor progression, without demonstrable OS benefit, supporting selective use. Retrospective and non-randomised, so treatment-selection bias cannot be excluded.

Abstract

ShowHide

Multicentre, international, retrospective quasi-experimental study (n=207 women with ER+/HER2- advanced breast cancer after CDK4/6 inhibitor progression). Everolimus + endocrine therapy (n=150) vs endocrine therapy alone (n=57). Median real-world PFS: 5.0 vs 4.3 months (adjusted HR 0.68, 95% CI 0.47-0.99). Time to everolimus failure: 4.2 months. No significant differences in time to chemotherapy or overall survival. Safety profile consistent with prior reports. Median follow-up 31.8 months.

Read the full abstract on PubMed →

At a glance

Evidence type	H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H.
Study type	3 - Human Observational
Model system	Human (multicenter retrospective cohort)
Journal	Breast Cancer Research and Treatment
Year	2026
Peer reviewed	Yes
Record last updated	2026-07-29
Source	DOI 10.1007/s10549-026-08012-5 · PMID 42429895

Extracted findings

Intervention	Everolimus (mTOR inhibitor) + endocrine therapy
Target	mTORC1
Model	Human
Effect	Modest PFS improvement (HR 0.68) in post-CDK4/6i ER+ breast cancer; no OS benefit demonstrated

In the Atlas

Cite this paper

ShowHide

Diogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, Bernardo Pereira, Leonor Vasconcelos de Matos, Leonor Fernandes, Guilherme Nader-Marta, Michel Moreau, Donatienne Taylor, Francois P Duhoux, & Evandro de Azambuja (2026). EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08012-5

@article{MAR2026,
  author       = {Diogo Martins-Branco and Soraia Lobo-Martins and Philippe Aftimos and Bernardo Pereira and Leonor Vasconcelos de Matos and Leonor Fernandes and Guilherme Nader-Marta and Michel Moreau and Donatienne Taylor and Francois P Duhoux and Evandro de Azambuja},
  title        = {{EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study}},
  journal      = {Breast Cancer Research and Treatment},
  year         = {2026},
  doi          = {10.1007/s10549-026-08012-5},
  note         = {PMID: 42429895},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record MAR2026) [Data set]. https://mtor-atlas.org/study/MAR2026/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_MAR2026,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record MAR2026},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/MAR2026/},
  doi          = {10.5281/zenodo.22059963}
}